Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.
Hims & Hers shares fell ~13% after the May 11 Q1 print as $608.1M revenue missed the $616.9M consensus and gross margin compressed from 73% to 65% on the compounded-semaglutide wind-down. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed); Canaccord raised to $32 from $30 (Buy). The Motley Fool published a 'Is HIMS Stock a Buy After Latest Dip?' analysis on May 14 framing the post-print decline as a buying opportunity, citing the 9% subscriber growth to 2.6M, the raised full-year guide ($2.8-3.0B revenue, $275-350M Adjusted EBITDA), and the structural lift from the Novo Nordisk branded-Wegovy distribution deal landing in Q2 books. The split between bullish and cautious analyst takes captures the central tension: high-growth telehealth navigating a margin-dilutive product transition.
The Precision Peptide Company (BPC) announced a strategic exclusive marketing partnership on May 8 with Mixed Martial Arts Group Limited (MMA), covering distribution of BPC's peptide product line through MMA's network of approximately 530,000 user profiles, 75,000 active students, and 800 verified gyms globally. The revenue-sharing arrangement splits net revenue 50/50 between the two companies for the first 12 months, then shifts to 75% BPC / 25% MMA for the remainder of the term. The deal taps into the broader consumer peptide wellness market projected to approach $300B (per the May 12 GlobeNewswire industry report) and signals the increasingly mainstream integration of peptide products into the combat-sports and broader athletic-performance distribution channels ahead of the July 23-24 PCAC meeting.
The 33rd European Congress on Obesity closes in Istanbul on Friday May 15 after four days that reframed the obesity-pharmacology conversation around two themes. First, maintenance: the SURMOUNT-MAINTAIN Lancet publication, ATTAIN-MAINTAIN Nature Medicine publication, and Wegovy STEP UP early-responder analyses gave prescribers Phase 3 evidence for dose tapering and switching strategies — moving past the 'how much weight will I lose' question to 'how do I stay there'. Second, guideline alignment: the EASO 2026 Nature Medicine framework formally privileged semaglutide and tirzepatide as first-line therapy across most obesity complications, with complication-specific differentiation (tirzepatide for OSA/MASH; semaglutide for OA/CVD/MASH-fibrosis). Caliway CBL-514 + GLP-1R combination preclinical data and Ascletis next-generation amylin and dual-incretin candidates rounded out the four-day program.
TIDES USA 2026 wrapped at the Hynes Convention Center in Boston on Thursday May 14 after four days of peptide and oligonucleotide CDMO programming. The CMC strategy tracks featured Bachem, PolyPeptide, CordenPharma, AmbioPharm, and Gilead on GMP capacity, large-scale SPPS economics, and the supply-chain economics of oral macromolecule manufacturing. The closing-day Robert Langer keynote framed peptide-LNP delivery as the next major engineering frontier. The conference concluded with Catalent's Zydis fast-dispersion + oral macromolecule platform presentations and Novo Nordisk's CMC strategy panel on oral semaglutide and the next-generation amycretin program. The week's combined manufacturing footprint (TIDES + the PolyPeptide EUR 200M credit facility on May 9 + the May 6 Lilly Lebanon $4.5B investment) anchors the CDMO buildout heading toward the 2028 capacity targets.
Eli Lilly's $7.8B Centessa Pharmaceuticals partnership announced in March 2026 continues to anchor the company's pipeline diversification beyond the GLP-1 franchise. Centessa's lead programs include orexin-2 receptor agonist peptides for narcolepsy and other CNS indications, with multiple Phase 1/2 readouts due across 2026-2027. The deal joins Lilly's $7B Kelonia Therapeutics acquisition (in vivo CAR-T platform) and $2.25B Profluent collaboration (AI-designed recombinase genetic medicine) as part of a multi-vertical diversification strategy. The $4.5B Lebanon Indiana LEAP District expansion announced May 6 (for Foundayo and retatrutide manufacturing) signals the GLP-1 franchise remains the cash cow, but the company is actively building optionality outside the obesity-pharmacology lane heading into the 2031 tirzepatide patent cliff.
The next Foundayo IQVIA prescription tracker update is expected from Citi mid-week May 18-20, covering the week ending May 8. Week 4 hit 7,335 prescriptions per the May 8 Citi note with Lilly executives citing 20,000 total patients (~35% via telehealth not captured in the retail-only IQVIA data). Citi's projected $146M Q2 revenue and $1.6B full-year 2026 estimate continue to anchor the analyst consensus. Lilly executives have asked analysts for 8-12 weeks of data before reading commercial trajectory through pharmacy-fill noise; the Week 5 reading is the first post-PBM-coverage-expansion data point as the two largest US PBMs went live with Foundayo coverage mid-May. The Wegovy pill remains roughly 60-70x ahead on weekly volume (>440K in the week ending May 1 per Novo's Q1 commentary).
Wall Street's read of Hims & Hers' Q1 print delivered May 11 split between two camps. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed) on what analysts called a 'mixed' quarter, citing gross margin compression from 73% to 65% on the wind-down of compounded semaglutide. Canaccord raised its target to $32 from $30 (Buy) framing the quarter as a transition speed bump rather than a thesis break. The central question both calls land on: whether branded Novo Nordisk Wegovy/Ozempic distribution (live since March 26) can offset margin loss from the compounded business. Q1 books closed March 31, so meaningful Wegovy revenue contribution comes in Q2; subscriber count held at 2.6M (+9% YoY).
Novo Nordisk CEO Mike Doustdar confirmed on the May 6 Q1 analyst call and in May 14 follow-up commentary that the Wegovy pill has surpassed 1 million cumulative US users 16 weeks after the January 5, 2026 launch. The pill posted DKK 2.26B (~$354M) in Q1 sales (nearly 2x analyst consensus) on roughly 1.3 million Q1 prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions per the Q1 IQVIA data. International expansion is targeted for H2 2026 with EU approval anticipated before year-end. The pill ramp is the cleanest near-term commercial signal for Novo against Lilly's tirzepatide franchise (Mounjaro/Zepbound), which displaced Keytruda as the world's #1 best-selling drug in Q1 2026.
ASCO 2026 abstracts will release on asco.org/abstracts beginning 5:00 PM ET on Wednesday May 21, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology slate is substantial: Pfizer announced 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions; Bicycle Therapeutics has an oral and four poster presentations on zelenectide pevedotin (BT8009, nectin-4 PDC) with Duravelo-2 interim data; Avacta has Phase Ia/Ib data on AVA6000 (FAP-Dox PDC) in salivary gland cancers; BioVaxys's MVP-S survivin peptide vaccine PESCO trial data; BriaCell's six Bria-IMT/Bria-OTS+ presentations on metastatic breast cancer; and Replimune's RP1 + nivolumab 3-year melanoma OS data. Crinetics CRN09682 SSTR2 NDC BRAVESST2 update expected.
Novo Nordisk Q1 management commentary delivered alongside the ECO 2026 data updates confirmed that the Wegovy pill (oral semaglutide 25 mg) will launch in select international markets in the second half of 2026 with European approval expected before year-end. The international rollout follows the January 5 US launch that delivered DKK 2.26B (~$354M) in Q1 sales — nearly double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and >2M cumulative US prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions; Novo tightened its full-year guidance to a 4-12% sales decline (from 5-13%). The international expansion is the inflection point for Novo's competitive positioning vs Lilly's Foundayo and the next-generation Mounjaro/Zepbound franchise.
A May 12 GlobeNewswire industry report frames the consumer peptide wellness market as approaching $300B globally on accelerating mainstream demand for science-backed peptide products spanning energy, recovery, metabolism, healthy aging, fitness, and overall well-being. The report tracks the post-Category-2 commercial cycle for BPC-157, TB-500, GHK-Cu, sermorelin, and the broader peptide supplement and cosmeceutical landscape — including OMI Wellbeauty's hair-growth peptides, Neurogan's 2% GHK-Cu body care, Auro Wellness's copper tripeptide serum, and the early-stage longevity peptide programs at Hims & Hers and LifeMD. The framing arrives six weeks ahead of the FDA's PCAC July 23-24 meeting that will decide compounding-pharmacy status for seven additional peptides including Emideltide (DSIP), Semax, and Epitalon.
Sector stock reaction across May 12-13: Novo Nordisk ADRs popped roughly 6% premarket May 12 on the early-responder + women's-data combination and the OASIS 4 mobility analyses; Eli Lilly traded flat as the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN dual publication confirmed expected maintenance positioning rather than producing fresh upside surprises. Analysts noted the broader 'long-term treatment' thesis — that GLP-1 obesity drugs are chronic-disease medications, not short courses — got concrete trial backing this week between SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN, and STEP UP early-responder analyses. The week's narrative shift sets up the May 14-15 ECO Day 3+4 cycle and the May 29-June 2 ASCO 2026 meeting in Chicago — where peptide-drug conjugates (Bicycle BT8009, Avacta AVA6000, Pfizer FAP-Dox) take the next round of clinical-data spotlights.
Bloomberg reported May 6 that Eli Lilly's Mounjaro displaced Merck's Keytruda as the world's best-selling pharmaceutical in Q1 2026 — $8.66B Mounjaro Q1 sales vs Keytruda's $7.9B Q1 sales. The Mounjaro+Zepbound combined tirzepatide platform generated $36.5B in 2025, outpacing Keytruda's $31.6B. Keytruda had held the #1 ranking since Q1 2023, when it displaced AbbVie's Humira. The shift is the first time a peptide therapeutic has taken the top spot since the historical run of insulin biosimilars. The narrative also frames Lilly's $4.5B Lebanon Indiana manufacturing recommitment and the broader $21B Indiana capital plan as the supply-chain answer to demand at that scale.
Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.
Hims & Hers reported Q1 2026 after market close May 11: revenue $608.1M (+4% YoY vs $586M prior year), missing the $616.9M consensus; subscribers up 9% to 2.6M; net loss of $92.1M ($0.41/share) vs $49.5M net income in Q1 2025. Gross margin compressed from 73% to 65% on the strategic pivot away from compounded semaglutide toward branded Novo Nordisk Wegovy/Ozempic supply (live since March 26). Q1 closed March 31 — meaningful Wegovy revenue contribution lands in Q2. Full-year 2026 guidance was raised: revenue to $2.8-3.0B and Adjusted EBITDA to $275-350M. The company is keeping limited compounded GLP-1 access alive alongside branded supply, threading the FDA April 30 503B bulks-list proposal.
Catalent's TIDES USA 2026 presence centers on oral macromolecule delivery — the bottleneck that has kept all but a handful of peptides off the oral-route market. The contract development and manufacturing organization is showcasing its Zydis fast-dispersion platform, ZipDose 3D-printed dose-form technology, and oral macromolecule delivery systems engineered for peptides and proteins up to ~100,000 Da. The portfolio targets the post-orforglipron oral-GLP-1 reference architecture: SNAC permeation enhancers (Novo Nordisk's oral semaglutide approach), lipidation chemistry, and protective formulation matrices. Catalent's positioning aligns with the broader CDMO build-out — PolyPeptide's May EUR 200M credit facility, CordenPharma's $500M Boulder SPPS expansion — converging on Boston this week.
Eli Lilly on May 6 cut the ribbon on Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — and committed an additional $4.5B across two more LEAP Research and Innovation District sites in Lebanon, Indiana. The new investment supports planned production of Foundayo (orforglipron), Lilly's only FDA-approved GLP-1 pill that does not require fasting or water restrictions, and retatrutide, the triple GLP-1/GIP/glucagon agonist in seven Phase 3 trials. Total Indiana capital commitments since 2020 now exceed $21B, with the LEAP District alone totaling $18B since 2022 — the largest capital project in Indiana history. The buildout will add more than 1,000 jobs by 2027 and gives Lilly a domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks.